|
T9698 |
UC2288
|
|
Mdm2
,
p53
|
|
UC2288 is a relatively selective p21 attenuator which is synthesized based Sorafenib. UC2288 attenuates p21 protein levels with minimal effect on p21 protein stability. |
|
T64079 |
Mutant p53 modulator-1
|
|
|
|
Mutant p53 modulator-1 is a mutant p53 modulator. mutant p53 modulator-1 is able to hinder the progression of cancers containing p53 mutations. |
|
T4459 |
PK11000
|
|
DNA Alkylator/Crosslinker
|
|
PK11000 is a p53 targeting compound, has anti-tumor activities through activation of unstable p53. |
|
T3184 |
Kevetrin hydrochloride
|
Thioureidobutyronitrile HCl,thioureido butyronitrile hydrochloride,4-Isothioureidobutyronitrile hydrochloride |
Mdm2
,
p53
|
|
Kevetrin hydrochloride (4-Isothioureidobutyronitrile hydrochloride) is a small molecule and activator of the tumor suppressor protein p53, with potential antineoplastic activity. |
|
T9320 |
YK-3-237
|
B-[2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl]boronic acid |
Sirtuin
|
|
YK-3-237 (B-[2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl]boronic acid) reduces acetylation of mtp53 and exhibits anti-proliferative effects toward triple-negative breast cancer (TNBC) cells ca... |
|
T6954 |
PRIMA-1
|
2,2-Bis(hydroxymethyl)-3-quinuclidinone,NSC-281668,PRIMA 1 |
Apoptosis
,
Others
,
Ferroptosis
,
Autophagy
|
|
PRIMA-1 (NSC-281668) is a mutant p53 reactivator. It induces apoptosis and inhibits growth of human tumors with mutant p53. |
|
T6910 |
NSC59984
|
|
p53
|
|
NSC59984, a p53 pathway activator, induces mutant p53 protein degradation and p73 activation. |
|
T21648 |
CP-31398 dihydrochloride
|
CP 31398 dihydrochloride |
p53
|
|
CP-31398 dihydrochloride is a p53 stabilizer which stabilizes the active conformation of p53 and promotes p53 activity in cancer cell lines with mutant or wild-type p53. |
|
T37042 |
SCH529074
|
SCH 529074 |
p53
|
|
SCH529074 is a selective activator of p53 (Ki = 1 μM) and can be used in studies about non-small-cell lung carcinoma. SCH529074 restores mutant p53 function and interrupts HDM2-mediated ubiquitination of wild Type p53. |
|
T4325 |
COTI-2
|
COTI 2,COTI2 |
Apoptosis
,
p53
|
|
COTI-2, an orally available thiosemicarbazone, is an activator of mutant forms of the p53 protein with potential antineoplastic activity. |
|
T6611 |
NSC697923
|
2-[(4-methylphenyl)sulfonyl]-5-nitrofuran |
E1/E2/E3 Enzyme
|
|
NSC-697923 (2-[(4-methylphenyl)sulfonyl]-5-nitrofuran), a potent inhibitor of UBE2N (ubiquitin-conjugating enzyme E2 N, Ubc13), exhibits its role in inducing cell death in neuroblastoma (NB) cells through two distinct me... |
|
T4414 |
Eprenetapopt
|
APR-246,PRIMA-1Met |
Apoptosis
,
Others
,
Ferroptosis
,
p53
,
Autophagy
|
|
Eprenetapopt (PRIMA-1Met) restores wild-type conformation and function to mutant p53, and triggers apoptosis in tumor cells. PRIMA-1MET also targets the selenoprotein thioredoxin reductase 1 (TrxR1), a key regulator of c... |
|
T60202 |
MMRi62
|
7-[(2,3-dichlorophenyl)-(pyridin-2-ylamino)methyl]quinolin-8-ol |
Ferroptosis
|
|
MMRi62 (7-[(2,3-dichlorophenyl)-(pyridin-2-ylamino)methyl]quinolin-8-ol), a ferroptosis inducer targeting MDM2-MDM4 (negative regulators of tumor suppressor p53). MMRi62 shows a P53-independent pro-apoptotic activity aga... |
|
T77768 |
BAY 1892005
|
|
p53
|
|
BAY 1892005 is a p53 protein modulator that targets the p53 condenser for the study of diseases associated with misfolded p53 protein |
|
T74324 |
NSC90616
|
|
|
|
NSC90616 is a mutant p53 rescue compound [1] . |
|
T73533 |
ADH-6
|
|
|
|
ADH-6, a tripyridylamide compound, impedes the self-assembly of the aggregation-nucleating subdomain of mutant p53 DNA-binding domain (DBD). By targeting and dissociating mutant p53 aggregates in human cancer cells, ADH-... |
|
T75517 |
Colletofragarone A2
|
|
|
|
Colletofragarone A2, isolated from the fungus Colletotrichum sp. (13S020), exhibits anti-cancer activity by inhibiting mutant p53 and HSP90. It promotes the degradation and aggregation of mutant p53, in turn suppressing ... |
|
T36934 |
PK7242 (maleate)
|
PK7242 (maleate) |
|
|
The protein p53, often called the 'guardian of the genome,' is a transcription factor that is activated in response to cellular stress (low oxygen levels, heat shock, DNA damage, etc.) and acts to prevent further prolife... |
|
T74443 |
ADH-6 TFA
|
|
|
|
ADH-6 TFA, a tripyridylamide compound, effectively disrupts the self-assembly of the aggregation-nucleating subdomain of mutant p53 DBD, thereby targeting and disassociating mutant p53 aggregates in human cancer cells. T... |
|
T72770 |
p53 Activator 5
|
|
|
|
P53 Activator 5 is a potent activator of p53, exhibiting a SC150 value of less than 0.05 mM. It effectively binds to mutant p53, restoring its DNA-binding capability. Additionally, P53 Activator 5 demonstrates significan... |
|
T72769 |
p53 Activator 3
|
|
|
|
p53 Activator 3 is a potent activator of p53, demonstrating notable efficacy with an SC150 value of less than 0.05 mM. It effectively binds to mutant p53, reinstating its DNA-binding capability, and exhibits anti-tumor a... |
|
T78378 |
PK7088
|
|
Others
|
|
PK7088, a pyrazole-based peptide, selectively reactivates mutant p53 to a conformation with wild-type characteristics, demonstrating anticancer activity in oncological studies [1]. |
|
T73234 |
USP7-IN-7
|
|
|
|
USP7-IN-7, a potent USP7 inhibitor, exhibits an IC50 value of <10 nM. Demonstrating cytotoxicity against both p53-mutant and p53 wild-type blood cancer, as well as neuroblastoma cell lines at low nanomolar concentrations... |
|
T79013 |
SLMP53-2
|
|
|
|
SLMP53-2 is a mutant p53 reactivator that restores the wild-type-like conformation and DNA-binding ability of mutp53-Y220C through enhanced interaction with Hsp70, thereby reinstating p53's transcriptional activity. This... |
|
T70941 |
CLR01 sodium
|
|
|
|
CLR01 is a molecular tweezer. CLR01 reduces aggregated, pathologic, and seeding-competent α-synuclein in experimental multiple system atrophy. CLR01 inhibits aberrant superoxide dismutase 1 (SOD1) self-assembly in vitro ... |
|
T83082 |
Anticancer agent 168
|
|
|
|
Compound D16 (Anticancer agent 168) is an inhibitor of DNA2 that induces apoptosis and cell-cycle arrest predominantly in the S-phase. It demonstrates anticancer efficacy and can counteract chemotherapy resistance in can... |
|
T35696 |
Olomoucine II
|
|
|
|
Olomoucine II is an inhibitor of cyclin-dependent kinases (CDKs; IC50s = 7.6, 0.1, 19.8, 0.45, and 0.06 μM for Cdk1, -2, -4, -7, and -9, respectively).1It is selective for CDKs over 10 additional kinases (IC50s = >100 μM... |
|
T78715 |
MS78
|
|
|
|
MS78, an acetylation targeting chimera (AceTAC), specifically acetylates the p53Y220C mutant by recruiting the histone acetyltransferase p300/CBP. This compound enhances the expression of TRAIL apoptotic genes while conc... |
|
T35874 |
CC260
|
|
|
|
CC260, a selective inhibitor for PI5P4Kα and PI5P4Kβ with Kis of 40 nM and 30 nM respectively, exhibits minimal to no inhibition against other protein kinases like Plk1 and RSK2. It is applicable in the research of cell ... |
